CompletedNot Applicable

Efficacy and Safety of Conventional Immunosuppressant Therapies in Elderly Patients With Neuromyelitis Optica Spectrum Disorder

2,985 participantsStarted 2011-01-01

Plain-language summary

Newly diagnosed NMOSD patients

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * From 2011 to 2022, newly diagnosed NMOSD patients.. Exclusion Criteria: * Patients had a history of cancer * Patients had used ISTs (excluding steroids) prior to the NMOSD diagnosis.

What they're measuring

Relapse

Timeframe: 1 year

Trial details

NCT IDNCT07032337

SponsorSamsung Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-12-31

View on ClinicalTrials.gov More Neuromyelitis Optica Spectrum Disorder (NMOSD) trials